# EDGAR Filing Document

**Accession Number:** 0001870404
**File Stem:** 0000000000-25-007857
**Filing Date:** 2025-7
**Character Count:** 2380
**Document Hash:** 4ce292d5ac340e54f084a752c0aa0714
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007857.hdr.sgml**: 20250826

**ACCESSION NUMBER**: 0000000000-25-007857

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250725

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CERO THERAPEUTICS HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001870404
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 871088814
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-288816

**BUSINESS ADDRESS:**
- **STREET 1:** 201 HASKINS WAY
- **STREET 2:** SUITE 230
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-407-2376

**MAIL ADDRESS:**
- **STREET 1:** 201 HASKINS WAY
- **STREET 2:** SUITE 230
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PHOENIX BIOTECH ACQUISITION CORP.
- **DATE OF NAME CHANGE:** 20210630
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-066152

## Text-Extract

```

                                                           July 25, 2025

Chris Ehrlich
Chief Executive Officer
CERO Therapeutics Holds, Inc.
201 Haskins Way, Suite 230
South San Francisco, CA 94080

        Re: CERO Therapeutics Holds, Inc.
            Registration Statement on Form S-1
            Filed July 21, 2025
            File No. 333-288816
Dear Chris Ehrlich:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Doris Stacey Gama at 202-551-3188 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Stephen M. Davis, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._